News
HZNP
78.76
+0.97%
0.76
Benzinga Pro's Top 5 Stocks To Watch For Wednesday, November 30, 2022: ADP, AMGN, SQM, BYND, MARA
Benzinga · 25m ago
iPhone Pro Shipments May Miss Consensus, Tesla Rival Charts Ambitious Expansion Plan In Mexico, Amazon Cloud Unit To Add More Employees: Top Stories Wednesday, Nov. 30
Benzinga · 45m ago
Horizon Therapeutics Shares Jump On Confirmation Of Takeover Talks With Several Large Companies
Benzinga · 1h ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 1h ago
Why Horizon Therapeutics Shares Are Trading Higher By Over 30%; Here Are 32 Stocks Moving Premarket
Benzinga · 1h ago
BRIEF-Horizon Therapeutics Confirms Preliminary Discussions Regarding Potential Offer
Reuters · 16h ago
Horizon Therapeutics fields buyout interest from Amgen, J&J and Sanofi
Reuters · 16h ago
Horizon Therapeutics Confirms Preliminary Discussions Regarding Potential Offer; Co In Discussions With Amgen, Janssen, Sanofi
Benzinga · 17h ago
Horizon Therapeutics plc Confirms Preliminary Discussions Regarding Potential Offer
DUBLIN, November 29, 2022--The Board of Horizon Therapeutics plc (Nasdaq: HZNP) ("Horizon" or the "Company") confirms that it is engaged in highly preliminary discussions with Amgen Inc., Janssen Global Services, LLC and Sanofi (each a "Possible Offeror") ...
Business Wire · 17h ago
Horizon Therapeutics (HZNP) is a Top-Ranked Value Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks · 6d ago
Xeris Biopharma Announces Research Collaboration And Option Agreement With Horizon Therapeutics plc For XeriJect Formulation Of Teprotumumab
Benzinga · 11/23 11:04
Xeris Biopharma Enters Collaboration With Horizon Therapeutics on Formulation of Thyroid Eye Disease Treatment
Xeris Biopharma Enters Collaboration With Horizon Therapeutics on Formulation of Thyroid Eye Disease Treatment
MT Newswires · 11/23 07:18
Horizon Therapeutics plc Announces Completion Of Enrollment Of Phase 3 Clinical Trial In Japan Evaluating TEPEZZA For The Treatment Of Active Thyroid Eye Disease
Benzinga · 11/16 13:16
Horizon Therapeutics plc Announces Scientific Collaboration with Leading Research Institution to Advance Research in Autoimmunity and Inflammation
DUBLIN, November 16, 2022--Horizon Therapeutics plc today announced that it has entered a multi-year scientific collaboration with Johns Hopkins University School of Medicine to identify new disease targets and develop therapies for patients with serious a...
Business Wire · 11/16 13:00
Horizon Therapeutics Completes Enrollment of Phase 3 Trial for Treatment of Active Thyroid Eye Disease in Japan
Horizon Therapeutics Completes Enrollment of Phase 3 Trial for Treatment of Active Thyroid Eye Disease in Japan
MT Newswires · 11/16 11:38
Horizon Therapeutics Teams Up With Johns Hopkins University School of Medicine for Autoimmunity, Inflammation Research
Horizon Therapeutics Teams Up With Johns Hopkins University School of Medicine for Autoimmunity, Inflammation Research
MT Newswires · 11/16 10:40
Paulson & Co. takes new stake in Rumble, exits SPDR Gold Trust ETF, DiDi Global
Seekingalpha · 11/14 23:31
Sustained Patient Response To KRYSTEXXA Injection With Methotrexate Compared To KRYSTEXXA Alone Shown Through Month 12 In MIRROR Randomized Controlled Trial
Benzinga · 11/08 15:01
Horizon Therapeutics Third Quarter 2022 Earnings: Beats Expectations
Horizon Therapeutics ( NASDAQ:HZNP ) Third Quarter 2022 Results Key Financial Results Revenue: US$925.4m (down 11% from...
Simply Wall St. · 11/08 13:26
Horizon Therapeutics ticks higher amid speculation of activist investor
Seekingalpha · 11/04 14:08
More
Webull provides a variety of real-time HZNP stock news. You can receive the latest news about Horizon Therapeutics Pub L through multiple platforms. This information may help you make smarter investment decisions.
About HZNP
Horizon Therapeutics plc is a global biotechnology company. The Company is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The Company's portfolio is composed of approximately 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. The Company operates through two segments: orphan segment and the inflammation segment. The orphan segment includes medicines, such as TEPEZZA (teprotumumab-trbw), KRYSTEXXA (pegloticase injection), RAVICTI (glycerol phenylbutyrate), PROCYSBI (cysteamine bitartrate), UPLIZNA (inebilizumab-cdon) injection, ACTIMMUNE (interferon gamma-1b) injection, BUPHENYL (sodium phenylbutyrate) tablets and powder, and QUINSAIR (levofloxacin) solution. The inflammation segment includes medicines, such as PENNSAID (diclofenac sodium topical solution), RAYOS (prednisone), VIMOVO (naproxen), and DUEXIS (ibuprofen).